Navigation Links
Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
Date:3/8/2013

d.com for more information.

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, any of the Janssen Pharmaceutical Companies and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  Neither Janssen Research & Development nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.

Media contacts:
'/>"/>

SOURCE Janssen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
10. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
11. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 FDNA présentera ... série de démonstrations personnelles   FDNA® ... de l,analyse de la dysmorphologie assistée par ... lors de la réunion ASHG 2014, qui se ... , en Californie. FDNA présentera la dernière ...
(Date:9/23/2014)... , September 23, 2014 ... l,automobile, la santé, le ferroviaire ou encore ... connectées, donneront progressivement accès à leurs données. ... nombreux capteurs installés au cœur des voitures, ... plusieurs dizaines de milliards le nombre de ...
(Date:9/23/2014)... ORLANDO, Fla. and DUBLIN ... Inc. (OTC-BB: TNIB) ("we" or the "Company"), a ... innovative therapies for autoimmune diseases in emerging nations, ... has approved our common stock for DTC,s Deposit ... Fast Automated Securities Transfer Service ("FAST") transfer agent ...
Breaking Medicine Technology:FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à l'ASHG 2014 2FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à l'ASHG 2014 3Altran transforme le big data du monde industriel en nouveau business 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 3TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 4
... July 11, 2007 /PRNewswire/ -- Inspiration,Biopharmaceuticals today ... development of new, proprietary forms of,recombinant Factor ... The data,were highlighted in an oral presentation ... of the International Society on Thrombosis and,Haemostasis ...
... Study in American Heart Journal , ,WINNIPEG, ... a cardiovascular focused, biopharmaceutical company,today announced that the ... Tirofiban and Sirolimus-Eluting,Stent Versus Abciximab and Bare Metal ... the July edition of the Journal,of the American ...
Cached Medicine Technology:Inspiration Biopharmaceuticals Presents Data From Hemophilia,Program at International Society On Thrombosis and Haemostasis,(ISTH) Annual Meeting 2Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 2Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 3Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 4Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 5
(Date:9/23/2014)... Sept. 23, 2014 (HealthDay News) -- Few ... also undergo behavioral therapy, and the rates vary ... new study finds. Medication alone can manage ... do better if they also receive behavioral therapy ... researchers analyzed data in more than 1,500 counties ...
(Date:9/23/2014)... an exercise DVD that adds short breaks of physical ... found it had a high level of popularity with ... overly sedentary educational programs. , Called "Brain Breaks," the ... Program of the Linus Pauling Institute at Oregon State ... children in 5-7 minute segments of physical activity, demonstrated ...
(Date:9/23/2014)... showing the benefits of preventing a reduction in ... was released today by the American College of ... Save the Medicaid Primary Care Pay Parity Program: ... Life-Saving Primary Care Will Expire," explains why it ... internists and pediatricians (and their related subspecialists), family ...
(Date:9/23/2014)... September 23, 2014 Vancouver Electrician Contractors, ... be offering commercial electrical services in Vancouver, BC. The ... whether it is a small maintenance project or a ... solution package to meet the needs of the individual ... services will be of an affordable price. As a ...
(Date:9/23/2014)... Dallas, Texas (PRWEB) September 23, 2014 ... market for allergic rhinitis (AR) is highly ... having different SIT formulations available, under different ... crossover between markets. Europe has the most ... immunotherapy (SLIT), and allergen immunotherapy tablets (AITs) ...
Breaking Medicine News(10 mins):Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 3Health News:Unless Congress acts, patients may soon lose access to primary care 2Health News:Unless Congress acts, patients may soon lose access to primary care 3Health News:Pro Ace Now Offers Commercial Electrical Services in Vancouver 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 4
... The new ... on the brand’s two-stage product program. , ... (Vocus) March 12, 2010 -- Metabolife launched Metabolife® Green Tea + Vitamin D3 ... and wellness. The new product, an extension of the stage-one product portfolio, builds on the ...
... ... ... U.S. HealthWorks , one of the nation’s largest operators of outpatient health care centers ... will host its 2nd healthcare symposium for U.S. HealthWorks Medical Group physicians and affiliated clinicians ...
... O.N.E., One Natural Experience debuts O.N.E. Active, an innovative ... extra mile.  O.N.E. Active provides the same all natural health ... O.N.E. Coconut Water -- but with the addition of ginkgo ... of sharpening the mind while engaging in sports or any ...
... Campaign to Generate One Million Emails to Congress , ... , , ... ... DALLAS , March 12 ...
... shift in daylight, experts say , , FRIDAY, March 12 (HealthDay ... time this Sunday because it starts to stay light longer, even ... , However, that shift may not be such a welcome change ... occurs in the fall and winter and is caused, at least ...
... heart failure by 20%. Silke Schmidt et al. present ... Deutsches rzteblatt International ( Dtsch Arztebl Int ... wide variety of clinical applications of electronic transfer of ... such as heart rate, blood pressure and oxygen saturation, ...
Cached Medicine News:Health News:Metabolife's New Green Tea + Vitamin D3 Helps Promote Bone Health and Supports Weight Management 2Health News:U.S. HealthWorks Hosts Healthcare Symposium 2Health News:All in O.N.E. ... O.N.E.(TM) Natural Experience Introduces O.N.E. Active(TM), a New Natural Sports Drink That Combines the Super Hydration Power of Coconut Water With Energizing Herbs and Minerals to Provide the Ultimate MIND/BODY Experience 2Health News:All in O.N.E. ... O.N.E.(TM) Natural Experience Introduces O.N.E. Active(TM), a New Natural Sports Drink That Combines the Super Hydration Power of Coconut Water With Energizing Herbs and Minerals to Provide the Ultimate MIND/BODY Experience 3Health News:All in O.N.E. ... O.N.E.(TM) Natural Experience Introduces O.N.E. Active(TM), a New Natural Sports Drink That Combines the Super Hydration Power of Coconut Water With Energizing Herbs and Minerals to Provide the Ultimate MIND/BODY Experience 4Health News:Think Tank & Radio Network Encourage Massive Resistance to ObamaCare 2Health News:Think Tank & Radio Network Encourage Massive Resistance to ObamaCare 3Health News:Think Tank & Radio Network Encourage Massive Resistance to ObamaCare 4Health News:Daylight Savings: Not a Bright Time for All 2Health News:Daylight Savings: Not a Bright Time for All 3
... AFX (Air Fluid eXchange) Lens ... designed for use in an ... its use as a primary ... low profile and sutureless design ...
... 30° Prism are designed for ... recommended for tractional retinal detachments ... retinal detachment. They can be ... other midperipheral laser applications. Direct ...
... High-Mag 1.5x is specifically designed ... in macular hole surgery, optic ... membrane removal, traditional macular edema ... magnification. This lens was developed ...
... Chalam Flat is designed for ... and induction of posterior vitreous ... for macula whole surgery, epiretinal ... tractional epiretinal membranes. Direct image ...
Medicine Products: